ICON CLINICAL RESEARCH (U.K.) NO. 6 LIMITEDActive

Company number 09743789Private limited companyIncorporated 2015

Key figures

£32,143,808-0.0%
Net assets 2024
+8.0%
Average annual growth 2021–2024
010 m20 m30 m40 m2021202220232024

ICON CLINICAL RESEARCH (U.K.) NO. 6 LIMITED does not disclose its turnover in its latest accounts; the profit for the year is as stated in the accounts.

Ratios

2024
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
020 m40 m2021202220232024
Filed accounts2021–2024
2021202220232024
Profit for the year22,987,1361,137,9115,502,701-1,251
Cash at bank and in hand7,08516,138166,098141,441
Total assets25,510,86726,647,71832,174,87932,153,167
Total liabilities7,2006,14030,60010,139
Net assets / total equity25,504,44726,642,35832,145,05932,143,808
Average number of employees3332

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: ICON CLINICAL RESEARCH (U.K.) NO. 6 LIMITED

Company

ICON CLINICAL RESEARCH (U.K.) NO. 6 LIMITED is a private limited company registered with Companies House under company number 09743789. It was incorporated on 21 Aug 2015. Its status is active. The registered office is in Reading (RG2). Its nature of business (SIC 2007) is activities of other holding companies n.e.c. (64209).

Accounts

The latest accounts in the database are for 2024 (period ending 31 Dec 2024); the company files full accounts. Loss for the year was £1,251. Net assets were £32,143,808, down 0% on the previous year. Cash at bank and in hand was £141,441. Total assets were £32,153,167 and total liabilities £10,139. The company had an average of 2 employees. Figures are available for 4 financial years (2021–2024).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 29 Mar 2027.